Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Br J Clin Pharmacol. 2022 Oct 12;89(3):1027–1035. doi: 10.1111/bcp.15546

Table 1.

Subject demographics.

Characteristic Metformin-treated subjects
(n=14)
Untreated control subject
(n=1)

Age (yr)
 median 70.5 75
 range (min, max) 62, 80 --

Sex
 male, n (%) 5 (36) 1 (100)
 female, n (%) 9 (64) --

Body weight
 median 87.5 97.2
 range (min, max) 56.2, 117.5 --

Body-mass index
 median 29.7 29.9
 range (min, max) 22.7, 46.6 --

History of T2DM, n (%) 13 (93) 0 (0)

Subject taking metformin at time of study entry, n (%) 13 (93) 0 (0)

Subjects enrolled 19 1
Subjects evaluable 14 1
Subjects non-evaluable 5 --
Reason for non-evaluability:
 withdrew due to adverse events* 1 --
 did not complete study treatment 2 --
 did not complete drug diary 2 --
*

One non-T2DM subject withdrew due to self-reported nausea and diarrhea that the subject attributed to study-prescribed metformin.